Bupropion Hydrochloride

Bupropion Hydrochloride
Product Description

Dipharma manufactures wide range of active pharmaceutical ingredients which includes Bupropion Hydrochloride. It belongs to commercial products category. Therapeutic category: Antidepressant. Contact us for more information.

Dipharma Francis Srl

  • IT
  • 2015
    On CPhI since
Specifications
  • CAS Registry Number
    31677-93-7

Dipharma Francis Srl

  • IT
  • 2015
    On CPhI since

More Products from Dipharma Francis Srl

  • Fexofenadine Hydrochloride

    Product Fexofenadine Hydrochloride

    Dipharma manufactures wide range of active pharmaceutical ingredients which includes Fexofenadine Hydrochloride. It belongs to commercial products category. Therapeutic category: Antihistaminic. Contact us for more information.
  • Nortriptyline Hydrochloride

    Product Nortriptyline Hydrochloride

    Dipharma manufactures wide range of active pharmaceutical ingredients which includes Nortriptyline Hydrochloride. It belongs to commercial products category. Therapeutic category: Antidepressant. Contact us for more information.
  • Ursodeoxycholic Acid

    Product Ursodeoxycholic Acid

    Dipharma manufactures wide range of active pharmaceutical ingredients which includes Ursodeoxycholic Acid. It belongs to commercial products category. Therapeutic category: Cholelitholytic Agent. Contact us for more information.
  • Aminocaproic Acid*

    Product Aminocaproic Acid*

    Dipharma manufactures wide range of Active Pharmaceutical Ingredients which includes Aminocaproic Acid*. It belongs to new products category. Therapeutic category: Treatment of bleeding disorders. Contact us for more information.
    * only for specific markets. See our web site
  • Amitriptyline Hydrochloride

    Product Amitriptyline Hydrochloride

    Dipharma manufactures wide range of active pharmaceutical ingredients which includes Amitriptyline Hydrochloride. It belongs to commercial products category. Therapeutic category: Antidepressant. Contact us for more information.
  • Bendroflumethiazide

    Product Bendroflumethiazide

    Dipharma manufactures wide range of active pharmaceutical ingredients which includes Bendroflumethiazide. It belongs to commercial products category. Therapeutic category: Diuretic. Contact us for more information.
  • Benserazide Hydrochloride

    Product Benserazide Hydrochloride

    Dipharma manufactures wide range of active pharmaceutical ingredients which includes Benserazide Hydrochloride. It belongs to new products category. Therapeutic category: Antiparkinson. Contact us for more information.
  • Biperiden  Hydrochloride

    Product Biperiden Hydrochloride

    Dipharma manufactures wide range of active pharmaceutical ingredients which includes Biperiden Hydrochloride. It belongs to new products category. Therapeutic category: Antiparkinson. Contact us for more information.
  • Chenodeoxycholic Acid*

    Product Chenodeoxycholic Acid*

    Dipharma manufactures wide range of active pharmaceutical ingredients which includes Chenodeoxycholic Acid*. It belongs to new products category. Therapeutic category: Bile Stone Therapy, Plain antitussives. Contact us for more information.

    * only for specific markets. See our web site
  • Cilostazol 

    Product Cilostazol 

    Dipharma manufactures wide range of active pharmaceutical ingredients which includes Cilostazol. It belongs to commercial products category. Therapeutic category: Platelet Aggregation Inhibitor. Contact us for more information.
  • Crisaborole

    Product Crisaborole

    Dipharma manufactures wide range of active pharmaceutical ingredients which includes Crisaborole. It belongs to new products category. Therapeutic category: Treatment of atopic dermatitis and psoriasis. Contact us for more information.
  • Cyclobenzaprine Hydrochloride

    Product Cyclobenzaprine Hydrochloride

    Dipharma manufactures wide range of active pharmaceutical ingredients which includes Cyclobenzaprine Hydrochloride. It belongs to commercial products category. Therapeutic category: Muscle Relaxant. Contact us for more information.

Dipharma Francis Srl resources

  • News Dipharma’s cGMP Pilot plant, expansion proceeding according to plan

    With an investment of €2.7 Million, the company continues to consolidate its position to be among the leading small molecule CDMOs. The new production line doubles the capacity of the existing pilot plant.
  • News Kalexsyn appoints Brian Eklov as new CEO

    Kalexsyn Inc. announced that its Board of Directors appointed Brian Eklov to succeed Robert Gadwood, who is retiring, as Chief Executive Officer and Board member.
  • News Dipharma builds cGMP manufacturing suite at US subsidiary

    Italy’s Dipharma Francis has completed construction of a new cGMP manufacturing suite at its US subsidiary, Kalexsyn, strengthening its service offering and ensuring continuity across the product lifecycle from preclinical to commercialisation , the contract research and development organization announced Monday.
  • News Dipharma Francis S.r.l. announces changes in the leadership positions

    Dipharma Francis S.r.l., (Dipharma), a leading European manufacturer of Active Pharmaceutical Ingredients, announced a series of changes in the leadership positions following the retirement of Mrs. Barbara Geinoz-Biazzi, Chairman.
  • News Dipharma Francis S.r.l. completes acquisition of Kalexsyn, Inc.

    Milan, ItalyDipharma Francis S.r.l., (Dipharma), a leading European manufacturer of Active Pharmaceutical Ingredients, is pleased to communicate that it has completed its previously announced acquisition of Kalexsyn, Inc. (Kalexsyn), a world-class Contract Research Organization (CRO) providing chemistry services to the biotechnology and pharmaceutical industry.

    Pursuant to an agreement dated March 19, 2018, Dipharma has acquired all of the issued and outstanding shares of Kalexsyn through its American subsidiary Dipharma, Inc.

    Kalexsyn, based in Kalamazoo, Michigan (USA), was founded in 2003 and provides chemistry services that support the drug discovery and development activities of their customers.

  • News Dipharma Francis S.r.l. enters into agreement to acquire Kalexsyn Inc.

    Dipharma Francis S.r.l. (Dipharma), a leading European manufacturer of Active Pharmaceutical Ingredients, and Kalexsyn, Inc. (Kalexsyn), a world-class Contract Research Organization (CRO) providing chemistry services to the biotechnology and pharmaceutical industry, are pleased to announce that Dipharma and Kalexsyn’s shareholders have entered into a definitive agreement pursuant to which Dipharma will acquire 100% control of Kalexsyn, through its American subsidiary Dipharma, Inc.
    The transaction is expected to close within a month.

Recommended products